A randomized open study to compare the efficacy and safety of GLP-1 analogue (Liraglutide) versus DPP-4 inhibitor (Vildagliptin) in patients with Type 2 Diabetes.
Latest Information Update: 01 Jun 2012
Price :
$35 *
At a glance
- Drugs Liraglutide (Primary) ; Vildagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 26 May 2012 Status changed from not stated to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.
- 09 Feb 2011 New trial record